Ph. Eur. 2.2.1 Clarity & Opalescence of Liquids (Visual Test, Acceptance Criteria, USP Comparison)

Ph. Eur. 2.2.1 (EP 2.2.1) defines the official European visual test for clarity and degree of opalescence of pharmaceutical liquids. It is used when a qualitative visual appearance limit (rather than a quantitative turbidity value) is required by a Ph. Eur. monograph or product specification.

Opalescence results from light scattering by undissolved particles or colloidal material, producing a hazy or milky appearance.

The test is commonly applied to injectable solutions, ophthalmic products, and other liquid preparations, with acceptance levels defined in the individual monographs.

The method relies on direct visual comparison against Reference Suspensions I–IV (formazin-based), which define increasing degrees of acceptable opalescence. Importantly, Ph. Eur. 2.2.1 is primarily a visual comparator method (Reference Suspensions I–IV) and monograph requirements are expressed in visual terms; while the chapter describes instrumental approaches/calibration, it is not to be treated as a product-specific numeric turbidity specification unless your control strategy explicitly establishes and validates one.

 

Methodology: Direct visual comparison of the sample with a reference (water or formazin suspension) in identical, colorless glass tubes, viewed vertically in diffused daylight or artificial light against a black background.

Reference Suspensions: Formazin suspensions I–IV provide reproducible visual standards of increasing opalescence. While these suspensions are prepared using formazin (prepared by reacting hydrazine sulfate with hexamethylenetetramine) the chapter defines them as visual reference standards rather than quantitative turbidity limits.

Acceptance Criteria:

A liquid is considered clear if it matches water/solvent or is not more opalescent than Reference Suspension I, under the prescribed conditions.

Compliance limits are then not more opalescent than the reference suspension prescribed in the monograph/specification.

 

Typical specification: Not more opalescent than Reference Suspension I, or clear when compared to water, as specified in the relevant Ph. Eur. monograph.

Harmonization & USP Alignment, Comparison Table:

Aspect	Ph. Eur. 2.2.1	USP Framework
Primary purpose	Visual assessment of clarity and degree of opalescence	Control of visible particulates and turbidity (via separate USP chapters and product specifications)
Method type	Visual comparison against Reference Suspensions I–IV	No standardized visual opalescence scale
Defined visual scale	Yes (Reference Suspensions I–IV)	No
Acceptance criteria	Defined in individual Ph. Eur. monographs referencing Suspensions I–IV	Defined in product-specific specifications.
Primary focus	Haze / opalescence	Visible particulates (USP <790>) and turbidity (USP <855>)
Instrumental option	Instrumental determination described (e.g., ratio turbidimetry) to support the visual comparator method; reference suspensions are associated with approximate NTU values, not intrinsic product limits.	USP <855> (nephelometry / turbidimetry) for quantitative turbidity
Typical regulatory use	Primary visual appearance test in EU/global filings when a defined opalescence scale is needed	Supplementary approach (particulates + turbidity) without a defined visual opalescence scale

There is no direct harmonized equivalent in the United States Pharmacopeia (USP) for this specific visual scale. [USP does have harmonized chapters for visible particulates (USP <790>, harmonized with Ph. Eur. 2.9.20) but these focus on particulate matter, not opalescence/haze]

USP Approach: USP <1> Injections requires products to be "essentially free from visible particulates," but does not define a "Reference Suspension I-IV" scale for haziness.

Instrumental Equivalent: For quantitative measurement of haze, USP <855> Nephelometry and Turbidimetry is the aligned instrumental standard.

For root-cause investigation of opalescence, complementary techniques such as DLS (ISO 22412) for particle sizing, or analytical ultracentrifugation for aggregate characterization, are commonly used to identify the source of light scattering.

Global Strategy: Because the USP does not define a standardized visual opalescence scale, Ph. Eur. 2.2.1 is often referenced in global submissions when a standardized visual comparator scale is needed (particularly where Ph. Eur. compliance is part of the filing strategy).

Applications in CMC and QC

Ph. Eur. 2.2.1 applies to:

• Parenteral injections and infusions (SVPs & LVPs)
• Ophthalmic solutions
• Biologics and gene therapy formulations (e.g., AAV, mRNA solutions)
• Raw materials and aqueous intermediates
• Solutions prone to precipitation or aggregation

Common Causes of Opalescence

• Protein aggregation (biologics, AAV capsids)
• Precipitation of salts or excipients
• Surfactant degradation (e.g., polysorbate hydrolysis)
• Air microbubbles
• Early microbial growth
• Interaction between formulation components (e.g., buffer-excipient precipitation)

Analyst Pitfalls

• Non-uniform lighting or incorrect background
• Glass defects (scratches, glue, fingerprints)
• Temperature differences (cold samples appear more opalescent)
• Inconsistent sample preparation or mixing
• Using aged or improperly stored reference suspensions
• Failing to equilibrate sample and reference to the same temperature